These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8759892)

  • 1. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1.
    Wijdenes J; Vooijs WC; Clément C; Post J; Morard F; Vita N; Laurent P; Sun RX; Klein B; Dore JM
    Br J Haematol; 1996 Aug; 94(2):318-23. PubMed ID: 8759892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1.
    Carbone A; Gloghini A; Gattei V; Degan M; Improta S; Aldinucci D; Canzonieri V; Perin T; Volpe R; Gaidano G; Zagonel V; Pinto A
    Blood; 1997 May; 89(10):3787-94. PubMed ID: 9160685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.
    Costes V; Magen V; Legouffe E; Durand L; Baldet P; Rossi JF; Klein B; Brochier J
    Hum Pathol; 1999 Dec; 30(12):1405-11. PubMed ID: 10667416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and location on syndecan-1 core protein of the epitopes of B-B2 and B-B4 monoclonal antibodies.
    Dore JM; Morard F; Vita N; Wijdenes J
    FEBS Lett; 1998 Apr; 426(1):67-70. PubMed ID: 9598980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
    Tai YT; Li X; Tong X; Santos D; Otsuki T; Catley L; Tournilhac O; Podar K; Hideshima T; Schlossman R; Richardson P; Munshi NC; Luqman M; Anderson KC
    Cancer Res; 2005 Jul; 65(13):5898-906. PubMed ID: 15994968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
    Tassone P; Goldmacher VS; Neri P; Gozzini A; Shammas MA; Whiteman KR; Hylander-Gans LL; Carrasco DR; Hideshima T; Shringarpure R; Shi J; Allam CK; Wijdenes J; Venuta S; Munshi NC; Anderson KC
    Blood; 2004 Dec; 104(12):3688-96. PubMed ID: 15292058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors.
    Noonan K; Matsui W; Serafini P; Carbley R; Tan G; Khalili J; Bonyhadi M; Levitsky H; Whartenby K; Borrello I
    Cancer Res; 2005 Mar; 65(5):2026-34. PubMed ID: 15753403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells.
    Gattei V; Godeas C; Degan M; Rossi FM; Aldinucci D; Pinto A
    Br J Haematol; 1999 Jan; 104(1):152-62. PubMed ID: 10027728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
    Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
    Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
    Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
    Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of an anti-CD138 immunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells.
    Post J; Vooijs WC; Bast BJ; De Gast GC
    Int J Cancer; 1999 Nov; 83(4):571-6. PubMed ID: 10508496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum syndecan-1 in patients with newly diagnosed monoclonal proteinemia.
    Schaar CG; Vermeer HJ; Wijermans PW; Huisman W; le Cessie S; Kluin-Nelemans HC
    Haematologica; 2005 Oct; 90(10):1437-8. PubMed ID: 16219583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells.
    Ragnarsson L; Strömberg T; Wijdenes J; Tötterman TH; Weigelt C
    Cancer Immunol Immunother; 2001 Sep; 50(7):382-90. PubMed ID: 11676398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.
    Jourdan M; Ferlin M; Legouffe E; Horvathova M; Liautard J; Rossi JF; Wijdenes J; Brochier J; Klein B
    Br J Haematol; 1998 Mar; 100(4):637-46. PubMed ID: 9531328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia.
    Witzig TE; Kimlinger T; Stenson M; Therneau T
    Leuk Lymphoma; 1998 Sep; 31(1-2):167-75. PubMed ID: 9720726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
    Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
    Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Syndecan-1 (CD138): an immunohistochemical marker of plasma cell tumors].
    Fakan F; Boudová L; Hejda C
    Cesk Patol; 2002 Jan; 38(1):33-6. PubMed ID: 11933459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis.
    Frassanito MA; Cusmai A; Iodice G; Dammacco F
    Blood; 2001 Jan; 97(2):483-9. PubMed ID: 11154226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of clonogenicity of human multiple myeloma by dendritic cells.
    Kukreja A; Hutchinson A; Dhodapkar K; Mazumder A; Vesole D; Angitapalli R; Jagannath S; Dhodapkar MV
    J Exp Med; 2006 Aug; 203(8):1859-65. PubMed ID: 16880256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.